Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

L. Crucitti; R. Crocchiolo; C. Toffalori; B. Mazzi; R. Greco; A. Signori; F. Sizzano; L. Chiesa; E. Zino; M. T. Lupo Stanghellini; A. Assanelli; M. G. Carrabba; S. Marktel; M. Marcatti; C. Bordignon; C. Corti; M. Bernardi; J. Peccatori; C. Bonini; K. Fleischhauer; F. Ciceri; L. Vago

doi:10.1038/leu.2014.314

Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

L. Crucitti, R. Crocchiolo, C. Toffalori, B. Mazzi, R. Greco, A. Signori, F. Sizzano, L. Chiesa, E. Zino, M. T. Lupo Stanghellini, A. Assanelli, M. G. Carrabba, S. Marktel, M. Marcatti, C. Bordignon, C. Corti, M. Bernardi, J. Peccatori, C. Bonini, K. FleischhauerF. Ciceri, L. Vago

Research output: Contribution to journal › Article › peer-review

Abstract

Genomic loss of the mismatched human leukocyte antigen (HLA) is a recently described mechanism of leukemia immune escape and relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Here we first evaluated its incidence, risk factors and outcome in 233 consecutive transplants from partially HLA-mismatched related and unrelated donors (MMRD and MMUD, respectively). We documented 84 relapses, 23 of which with HLA loss. All the HLA loss relapses occurred after MMRD HSCT, and 2023 in patients with acute myeloid leukemia. Upon MMRD HSCT, HLA loss variants accounted for 33% of the relapses (2369), occurring later than their 'classical' counterparts (median: 307 vs 88 days, P

Original language	English
Pages (from-to)	1143-1152
Number of pages	10
Journal	Leukemia
Volume	29
Issue number	5
DOIs	https://doi.org/10.1038/leu.2014.314
Publication status	Published - May 11 2015

ASJC Scopus subject areas

Hematology
Cancer Research
Anesthesiology and Pain Medicine
Medicine(all)

Access to Document

10.1038/leu.2014.314

Cite this

Crucitti, L., Crocchiolo, R., Toffalori, C., Mazzi, B., Greco, R., Signori, A., Sizzano, F., Chiesa, L., Zino, E., Lupo Stanghellini, M. T., Assanelli, A., Carrabba, M. G., Marktel, S., Marcatti, M., Bordignon, C., Corti, C., Bernardi, M., Peccatori, J., Bonini, C., ... Vago, L. (2015). Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia, 29(5), 1143-1152. https://doi.org/10.1038/leu.2014.314

Crucitti, L, Crocchiolo, R, Toffalori, C, Mazzi, B, Greco, R, Signori, A, Sizzano, F, Chiesa, L, Zino, E, Lupo Stanghellini, MT, Assanelli, A, Carrabba, MG, Marktel, S , Marcatti, M, Bordignon, C, Corti, C, Bernardi, M , Peccatori, J , Bonini, C, Fleischhauer, K, Ciceri, F & Vago, L 2015, 'Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation', Leukemia, vol. 29, no. 5, pp. 1143-1152. https://doi.org/10.1038/leu.2014.314

@article{031b63e2119e4aa9ae280b1e17cf9de4,

title = "Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation",

abstract = "Genomic loss of the mismatched human leukocyte antigen (HLA) is a recently described mechanism of leukemia immune escape and relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Here we first evaluated its incidence, risk factors and outcome in 233 consecutive transplants from partially HLA-mismatched related and unrelated donors (MMRD and MMUD, respectively). We documented 84 relapses, 23 of which with HLA loss. All the HLA loss relapses occurred after MMRD HSCT, and 2023 in patients with acute myeloid leukemia. Upon MMRD HSCT, HLA loss variants accounted for 33% of the relapses (2369), occurring later than their 'classical' counterparts (median: 307 vs 88 days, P",

author = "L. Crucitti and R. Crocchiolo and C. Toffalori and B. Mazzi and R. Greco and A. Signori and F. Sizzano and L. Chiesa and E. Zino and {Lupo Stanghellini}, {M. T.} and A. Assanelli and Carrabba, {M. G.} and S. Marktel and M. Marcatti and C. Bordignon and C. Corti and M. Bernardi and J. Peccatori and C. Bonini and K. Fleischhauer and F. Ciceri and L. Vago",

year = "2015",

month = may,

day = "11",

doi = "10.1038/leu.2014.314",

language = "English",

volume = "29",

pages = "1143--1152",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

AU - Crucitti, L.

AU - Crocchiolo, R.

AU - Toffalori, C.

AU - Mazzi, B.

AU - Greco, R.

AU - Signori, A.

AU - Sizzano, F.

AU - Chiesa, L.

AU - Zino, E.

AU - Lupo Stanghellini, M. T.

AU - Assanelli, A.

AU - Carrabba, M. G.

AU - Marktel, S.

AU - Marcatti, M.

AU - Bordignon, C.

AU - Corti, C.

AU - Bernardi, M.

AU - Peccatori, J.

AU - Bonini, C.

AU - Fleischhauer, K.

AU - Ciceri, F.

AU - Vago, L.

PY - 2015/5/11

Y1 - 2015/5/11

N2 - Genomic loss of the mismatched human leukocyte antigen (HLA) is a recently described mechanism of leukemia immune escape and relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Here we first evaluated its incidence, risk factors and outcome in 233 consecutive transplants from partially HLA-mismatched related and unrelated donors (MMRD and MMUD, respectively). We documented 84 relapses, 23 of which with HLA loss. All the HLA loss relapses occurred after MMRD HSCT, and 2023 in patients with acute myeloid leukemia. Upon MMRD HSCT, HLA loss variants accounted for 33% of the relapses (2369), occurring later than their 'classical' counterparts (median: 307 vs 88 days, P

AB - Genomic loss of the mismatched human leukocyte antigen (HLA) is a recently described mechanism of leukemia immune escape and relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Here we first evaluated its incidence, risk factors and outcome in 233 consecutive transplants from partially HLA-mismatched related and unrelated donors (MMRD and MMUD, respectively). We documented 84 relapses, 23 of which with HLA loss. All the HLA loss relapses occurred after MMRD HSCT, and 2023 in patients with acute myeloid leukemia. Upon MMRD HSCT, HLA loss variants accounted for 33% of the relapses (2369), occurring later than their 'classical' counterparts (median: 307 vs 88 days, P

UR - http://www.scopus.com/inward/record.url?scp=84929280131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929280131&partnerID=8YFLogxK

U2 - 10.1038/leu.2014.314

DO - 10.1038/leu.2014.314

M3 - Article

C2 - 25371177

AN - SCOPUS:84929280131

SN - 0887-6924

VL - 29

SP - 1143

EP - 1152

JO - Leukemia

JF - Leukemia

IS - 5

ER -

Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this